Nektar Therapeutics (NKTR) released Loss for its first quarter that increased from last year and missed the Street estimates.
The company's bottom line came in at -$50.88 million, or -$0.24 per share. This compares with -$36.80 million, or -$0.19 per share, last year.
Analysts on average had expected the company to earn -$0.19 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period fell 51.7% to $10.460 million from $21.639 million last year.
Nektar Therapeutics earnings at a glance (GAAP) :
-Earnings: -$50.88 Mln. vs. -$36.80 Mln. last year.-EPS: -$0.24 vs. -$0.19 last year.-Revenue: $10.460 Mln vs. $21.639 Mln last year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.